2024 AGM Presentation
ASX Announcement General iTrack Molteno3 AlphaRET
21 Nov, 2024
September 2024 Quarterly Activities Report and Appendix 4C
ASX Announcement General iTrack Molteno3 AlphaRET
31 Oct, 2024
Notice of Annual General Meeting 2024
ASX Announcement General iTrack Molteno3 AlphaRET
18 Oct, 2024
Date of AGM and Closing Date for Director Nominations
ASX Announcement General iTrack Molteno3 AlphaRET
27 Sept, 2024
FY2024 Appendix 4G and Governance Statement
ASX Announcement General iTrack Molteno3 AlphaRET
26 Aug, 2024
FY2024 Appendix 4E and Annual Report
ASX Announcement General iTrack Molteno3 AlphaRET
26 Aug, 2024
FY2024 ASX Results Announcement
ASX Announcement General iTrack Molteno3 AlphaRET
26 Aug, 2024
FY2024 Results Presentation
ASX Announcement General iTrack Molteno3 AlphaRET
26 Aug, 2024
Record Sales Result in FY24
ASX Announcement General iTrack Molteno3 AlphaRET
8 July, 2024
Presentation on FY24 Sales
ASX Announcement General iTrack Molteno3 AlphaRET
8 July, 2024
USA Medicare Reimbursement Update
ASX Announcement iTrack
31 May, 2024
Ceasing to be a substantial holder
ASX Announcement General iTrack Molteno3 AlphaRET
20 Mar, 2024
Change in substantial shareholding from AEF
ASX Announcement General iTrack Molteno3 AlphaRET
20 Mar, 2024
Change of Director's Interest Notice VP
ASX Announcement General iTrack Molteno3 AlphaRET
19 Mar, 2024
Change of Director's Interest Notice VP
ASX Announcement General iTrack Molteno3 AlphaRET
19 Mar, 2024
Change of Director's Interest Notice
ASX Announcement General iTrack Molteno3 AlphaRET
19 Mar, 2024
Retail Entitlement Offer Complete
ASX Announcement General iTrack Molteno3 AlphaRET
15 Mar, 2024
Record USA Sales for February 2024
ASX Announcement General iTrack Molteno3 AlphaRET
5 Mar, 2024
Half Yearly Report and Accounts
ASX Announcement General iTrack Molteno3 AlphaRET
23 Feb, 2024
Cleansing Notice
ASX Announcement General iTrack Molteno3 AlphaRET
23 Feb, 2024
Retail Entitlement Offer Booklet
ASX Announcement General iTrack Molteno3 AlphaRET
19 Feb, 2024
Despatch of Entitlement offer Completed
ASX Announcement General iTrack Molteno3 AlphaRET
19 Feb, 2024
Appendix 3B - Proposed Issue of Securities
ASX Announcement General iTrack Molteno3 AlphaRET
14 Feb, 2024
EYE Placement & Institutional Offer Completion
ASX Announcement General iTrack Molteno3 AlphaRET
14 Feb, 2024
Investor Presentation
ASX Announcement General iTrack Molteno3 AlphaRET
12 Feb, 2024
Proposed issue of securities
ASX Announcement General iTrack Molteno3 AlphaRET
12 Feb, 2024
Cleansing Notice - Notice under section 708AA(2)(f) of the Corporations Act 2001 (Cth)
ASX Announcement General iTrack Molteno3 AlphaRET
12 Feb, 2024
Capital Raise for Expansion
ASX Announcement General iTrack Molteno3 AlphaRET
12 Feb, 2024
Trading Halt
ASX Announcement General iTrack Molteno3 AlphaRET
12 Feb, 2024
USA Sales Update
ASX Announcement iTrack
8 Jan, 2024
Response to ASX Aware Query
ASX Announcement General iTrack Molteno3 AlphaRET
4 Jan, 2024
USA Medicare Changes Withdrawn
ASX Announcement General iTrack Molteno3 AlphaRET
29 Dec, 2023
Deferral of Proposed USA Medicare Changes
ASX Announcement General iTrack Molteno3 AlphaRET
8 Dec, 2023
Further Update of Proposed USA Medicare Changes
ASX Announcement General iTrack Molteno3 AlphaRET
28 Nov, 2023
AGM Presentation
ASX Announcement General iTrack Molteno3 AlphaRET
23 Nov, 2023
Further Update on Proposed USA Medicare Changes
ASX Announcement General iTrack Molteno3 AlphaRET
14 Nov, 2023
Trading Halt
ASX Announcement General iTrack Molteno3 AlphaRET
10 Nov, 2023
Proposed USA Medicare Changes
ASX Announcement General iTrack Molteno3 AlphaRET
31 Oct, 2023
Trading Halt
ASX Announcement General iTrack Molteno3 AlphaRET
27 Oct, 2023
Preliminary Clinical Results Shows Potential For Addressable Market
ASX Announcement iTrack
25 Oct, 2023
Notice of Annual General Meeting
ASX Announcement General iTrack Molteno3 AlphaRET
20 Oct, 2023
Date of AGM & Closing Date for Director Nominations
ASX Announcement General iTrack Molteno3 AlphaRET
25 Sept, 2023
INVESTOR WEBINAR PRESENTATION - SHARECAFE
ASX Announcement General iTrack Molteno3 AlphaRET
15 Sept, 2023
Evans & Partners Small Cap Healthcare Conference Presentation
ASX Announcement General iTrack Molteno3 AlphaRET
12 Sept, 2023
EYE FY2023 Appendix 4E and Annual Report
ASX Announcement General iTrack Molteno3 AlphaRET
28 Aug, 2023
EYE FY2023 Results Presentation
ASX Announcement General iTrack Molteno3 AlphaRET
28 Aug, 2023
EYE FY2023 Results Announcement
ASX Announcement General iTrack Molteno3 AlphaRET
28 Aug, 2023
EYE FY2023 Appendix 4G and Governance Statement
ASX Announcement General iTrack Molteno3 AlphaRET
28 Aug, 2023
Investor Webinar Full Year (FY23) Results
ASX Announcement General iTrack Molteno3 AlphaRET
23 Aug, 2023
TechKnow Invest Roadshow Presentation August 2023
ASX Announcement General iTrack Molteno3 AlphaRET
3 Aug, 2023
iTrack™ Advance Sales in the USA Driving Strong Results
ASX Announcement General iTrack Molteno3 AlphaRET
2 Aug, 2023
Investor Presentation - ShareCafe
ASX Announcement General iTrack Molteno3 AlphaRET
19 May, 2023
Application for Quotation of Securities
ASX Announcement General iTrack Molteno3 AlphaRET
5 May, 2023
Cleansing Notice
ASX Announcement General iTrack Molteno3 AlphaRET
5 May, 2023
iTrack Advance First Surgeries and Sales in USA
ASX Announcement General iTrack Molteno3 AlphaRET
1 May, 2023
FDA Clears iTrack Advance for US Launch
ASX Announcement General iTrack Molteno3 AlphaRET
31 Mar, 2023
Notice of General Meeting
ASX Announcement General iTrack Molteno3 AlphaRET
28 Mar, 2023
Application for Quotation of Securities
ASX Announcement General iTrack Molteno3 AlphaRET
8 Mar, 2023
Cleansing Notice
ASX Announcement General iTrack Molteno3 AlphaRET
8 Mar, 2023
Reinstatement to Quotation
ASX Announcement General iTrack Molteno3 AlphaRET
2 Mar, 2023
Proposed issue of securities - 2 March 2023
ASX Announcement General iTrack Molteno3 AlphaRET
2 Mar, 2023
Half Yearly Accounts 31 December 2022
ASX Announcement General iTrack Molteno3 AlphaRET
2 Mar, 2023
Investor Presentation Half Year Results 31 Dec 2022
ASX Announcement General iTrack Molteno3 AlphaRET
2 Mar, 2023
Nova Eye Completes $8m Placement
ASX Announcement General iTrack Molteno3 AlphaRET
2 Mar, 2023
Suspension from Official Quotation
ASX Announcement General iTrack Molteno3 AlphaRET
28 Feb, 2023
Trading Halt
ASX Announcement General iTrack Molteno3 AlphaRET
27 Feb, 2023
Glaucoma Surgical Devices Sales Update
ASX Announcement General iTrack
31 Jan, 2023
Additional Clinical Role for 2RT
ASX Announcement AlphaRET
25 Jan, 2023
Status of Market Clearance for iTrack Advance in the USA
ASX Announcement General iTrack Molteno3 AlphaRET
12 Dec, 2022
AGM Presentation 2022
ASX Announcement General iTrack Molteno3 AlphaRET
17 Nov, 2022
Glaucoma Surgical Devices Sales Update
ASX Announcement General iTrack Molteno3 AlphaRET
16 Nov, 2022
AlphaRET Completes Initial Recruitment of Investigator Sites for 2RT® Confirmatory Pivotal Study
ASX Announcement General iTrack AlphaRET
24 Oct, 2022
Notice of Annual General Meeting
ASX Announcement General iTrack Molteno3 AlphaRET
14 Oct, 2022
2RT Presentation Professor Robyn H Guymer Today 15 Sept 2022
ASX Announcement General AlphaRET
15 Sept, 2022
AGM Date and Directors Nominations
ASX Announcement General iTrack Molteno3 AlphaRET
14 Sept, 2022
EYE 2RT Webinar Prof Guymer
ASX Announcement General iTrack Molteno3 AlphaRET
9 Sept, 2022
EYE FY22 Appendix 4G & Governance Statement
ASX Announcement General iTrack Molteno3 AlphaRET
26 Aug, 2022
EYE FY22 Results Presentation
ASX Announcement General iTrack Molteno3 AlphaRET
26 Aug, 2022
EYE FY22 Results Announcement
ASX Announcement General iTrack Molteno3 AlphaRET
26 Aug, 2022
EYE FY22 Appendix 4E & Annual Report
ASX Announcement General iTrack Molteno3 AlphaRET
26 Aug, 2022
Sales Performance Glaucoma Surgical Devices Segment
ASX Announcement General iTrack Molteno3
8 July, 2022
Nova Eye Medical Launches iTrack Advance
ASX Announcement General iTrack Molteno3 AlphaRET
8 June, 2022
2RT Pivotal Study and Regulatory Pathway Presentation
ASX Announcement General AlphaRET
3 May, 2022
Nova Eye Medical Announces Regulatory Pathway for AlphaRET 2RT in the USA
ASX Announcement General AlphaRET
3 May, 2022
EYE Appointment to AGS Board
ASX Announcement iTrack
31 Mar, 2022
Investor Presentation Half Year Results 31 December 2021
ASX Announcement General iTrack Molteno3 AlphaRET
17 Feb, 2022
Global Revenue of A$6.5m for 6 Months Ended 31 Dec 2021
ASX Announcement General iTrack Molteno3 AlphaRET
17 Feb, 2022
Half Yearly Report and Accounts
ASX Announcement General iTrack Molteno3 AlphaRET
17 Feb, 2022
Glaucoma Sales Update for 6 Months Ended 31 Dec 2021
ASX Announcement General iTrack
1 Feb, 2022
Presentation - Reducing Progression Rate of Age-Related Macular Degeneration
ASX Announcement General AlphaRET
21 Dec, 2021
Appendix 3Z Final Director's Interest Notice
ASX Announcement General
25 Nov, 2021
2021 Annual General Meeting Voting Results
ASX Announcement General
25 Nov, 2021
Presentation - Annual General Meeting 2021
ASX Announcement General
24 Nov, 2021
Withdrawal of AGM Resolutions 2,4,6,7,8 and 9 From Notice of Meeting
ASX Announcement General
24 Nov, 2021
Resignation of Mr Alex Sundich
ASX Announcement General
24 Nov, 2021
Jobkeeper Payments Notification
ASX Announcement General
11 Nov, 2021
US Government Stimulus Loan Forgiven
ASX Announcement General
26 Oct, 2021
Notice of Annual General Meeting
ASX Announcement General
21 Oct, 2021
5-Year Efficacy and Safety of iTrack™ to be Spotlighted at ESCRS 2021
ASX Announcement General iTrack Molteno3 AlphaRET
7 Oct, 2021
EYE FY21 Date of AGM & Closing Date for Director Nominations
ASX Announcement General iTrack Molteno3 AlphaRET
30 Sept, 2021
Nova Eye Medical to Present at ASX Small to Mid-Cap Conference
ASX Announcement General iTrack Molteno3 AlphaRET
10 Sept, 2021
Nova Eye Medical Acquires Key Glaucoma Patents to Drive New Product Expansion
ASX Announcement General iTrack
26 Aug, 2021
Nova Eye Medical Reports 25% Growth in Glaucoma Device Sales for the 2021 Fiscal Year
ASX Announcement General
19 Aug, 2021
Appendix 4E
ASX Announcement General
19 Aug, 2021
Appendix 4G & Corporate Governance Statement
ASX Announcement General
19 Aug, 2021
Notice of Upcoming Investor Call – Full Year (FY21) Results
ASX Announcement General
11 Aug, 2021
Notice of change of interests of substantial holder
ASX Announcement General
29 July, 2021
Nova Eye Medical FY21 Trading Update
ASX Announcement General
20 July, 2021
Nova Eye Establishes Share Sale Facility for Unmarketable Parcels
ASX Announcement General
15 July, 2021
Nova Eye Medical Files IDE Application with the FDA to Commence a Pivotal Study in the US Evaluating 2RT
ASX Announcement AlphaRET
5 July, 2021
2RT® Featured at the 2021 Meeting of the Association for Research in Vision and Ophthalmology
ASX Announcement General AlphaRET
3 May, 2021
Notice of Change of Interests of Substantial Holder
ASX Announcement General
30 Apr, 2021
First Patient Enrolled in MAGIC Clinical Trial for Glaucoma
ASX Announcement General iTrack
30 Apr, 2021
Five-Year Post-LEAD Review Shows Improvement in 2RT® Treatment Benefits for iAMD
ASX Announcement General AlphaRET
5 Mar, 2021
Clinical Trial to Assess Efficacy and Safety of iTrack™ in the Treatment of Mild to Moderate Glaucoma
ASX Announcement General iTrack
2 Mar, 2021
First Half FY2021 Accounts
ASX Announcement General
25 Feb, 2021
1HFY21: Growth in Glaucoma Surgical Devices Segment Despite Pandemic
ASX Announcement General
25 Feb, 2021
Notice of Upcoming Investor Call – First Half FY21 Results
ASX Announcement General
18 Feb, 2021
Notice of Change of Interests of Substantial holder
ASX Announcement General
14 Dec, 2020
Appendix 2A
ASX Announcement General
9 Dec, 2020
Poll Results Annual General Meeting 2020
ASX Announcement General
27 Nov, 2020
Chairman’s Address to Annual General Meeting
ASX Announcement General
27 Nov, 2020
PRESENTATION AND UPDATE, ANNUAL GENERAL MEETING 2020
ASX Announcement General
27 Nov, 2020
Strong Rebound for Glaucoma Surgical Device Sales in FY21
ASX Announcement General
25 Nov, 2020
2RT® Clinical Update: Sub-Study Analysis of LEAD Trial Demonstrates Improved Retinal Function Following Treatment with 2RT®
ASX Announcement General
16 Nov, 2020
Notice of Annual General Meeting
ASX Announcement General
26 Oct, 2020
Nova Eye Medical Establishes AlphaRET to Support Commercial Development of 2RT®
ASX Announcement AlphaRET
26 Oct, 2020
Date of AGM and Closing Date for Director Nominations
ASX Announcement General
8 Oct, 2020
Change in Substantial Holding (Australian Ethical)
ASX Announcement General
18 Sept, 2020
Change in Substantial Holding (Australian Ethical)
ASX Announcement General
10 Sept, 2020
New Director Appointment
ASX Announcement General
31 Aug, 2020
Notice of Upcoming Investor Call
ASX Announcement General
28 Aug, 2020
Nova Eye Records FY20 Net Profit After Tax of $35.7 Million
ASX Announcement General
28 Aug, 2020
Multicentre Study Highlights Surgical Efficiency of the Molteno3® Glaucoma Drainage Device
ASX Announcement Molteno3
5 Aug, 2020
Nova Eye Medical Completes Acquisition of Molteno Ophthalmology Assets
ASX Announcement General Molteno3
3 Aug, 2020
Payment to Shareholders of Capital Return and Dividend
ASX Announcement General
29 July, 2020
Updated Timetable for Capital Return & Dividend Payment
ASX Announcement General
16 July, 2020
Nova Eye Medical Expands Glaucoma Treatment Portfolio Through Acquisition of the Molteno3®
ASX Announcement General Molteno3
2 July, 2020
Appendix 3Z (Mangano)
ASX Announcement General
30 June, 2020
Appendix 3X (Spurling)
ASX Announcement General
30 June, 2020
Appendix 4E & Annual Report
ASX Announcement General
30 June, 2020
ASX ELX Completion Announcement
ASX Announcement General
30 June, 2020
For investor enquires please contact:
Mark Flynn
Nova Eye Medical Limited
W +61 416 068 733
mflynn@nova-eye.com
This website uses cookies to ensure you get the best experience on our website.
The cookies do not store any personalised information. Learn More
The cookies do not store any personalised information. Learn More